U.S., July 8 -- ClinicalTrials.gov registry received information related to the study (NCT07686588) titled 'Sacituzumab Tirumotecan Plus Immunotherapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma' on June 30.
Brief Summary: This is a single-center, open-label phase 2 study evaluating sacituzumab tirumotecan in combination with an immune checkpoint inhibitor in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma.
Eligible patients will have recurrent or metastatic head and neck squamous cell carcinoma that has progressed after prior standard therapy including an immune checkpoint inhibitor. Sacituzumab tirumotecan, a TROP2-directed antibody-drug conjugate, will be administered...